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Proteomic approach in the search of new cardiovascular
biomarkers. With the increasing incidence of cardiovascular dis-
eases worldwide, specifically atherosclerosis and heart failure,
the search for novel biomarkers remains a priority. As opposed
to complex diagnostic techniques that may not be suitable to
be applied to the wider population, biomarkers are useful for
population screening. The search for novel biomarkers is based
on knowledge of the molecular and cellular processes that take
place in the development of a specific disease. Atherosclerosis
and heart failure are characterized by a long period of silent
disease progression, allowing early diagnosis and the poten-
tial of early therapeutic intervention. The use of the so-called
proteomic techniques allows not only protein identification but
partial characterization, which includes expression and also
post-translational modification of these proteins. This allows
for the discovery of previously unknown proteins involved in
cardiovascular diseases, including some that may be suitable
to be used as biomarkers. However, to approach this issue, we
have to overcome difficulties such as tissue heterogeneity (ves-
sel wall or myocardium) and the lack of fresh human samples.
We discuss the proteomic study of human plaques, secreted pro-
teins by pathologic and normal vessel wall, and left ventricular
hypertrophy as potential sources of new biologic markers of
cardiovascular disease.
Cardiovascular diseases (CVD), including myocardial
infarction, heart failure, stroke, and peripheral arte-
rial disease, are among the leading causes of morbid-
ity and mortality in Western societies and developing
countries. The thrombotic complication of atheroscle-
rosis is one of the higher prevalent processes leading
to CVD. In atherosclerosis, hemodynamic, thrombotic,
and carbohydrate-lipid metabolic variables merge, lead-
ing to a chronic vascular wall inflammatory process [1,
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2] that, after decades of asymptomatic progress, may
ultimately lead to life-threatening events. The main mech-
anism involved is the rupture/erosion of an atheroscle-
rotic plaque, allowing the interaction between the lipid
core and other highly thrombogenic plaque components
with flowing blood. This initiates a platelet-dependent
thrombus that may progress to totally occlude the lumen
and/or be the source of thromboembolic events [3, 4].
Atherosclerosis of the coronaries, carotids, aortic arch,
abdominal aorta, and iliac-femoral arteries leads to the
most common clinical manifestations of atherothrombo-
sis: myocardial infarction, unstable angina, stroke, and
transient cerebral ischemia, and intermittent claudication
and gangrene that jeopardize limb viability [5].
Heart failure prevalence and incidence are increasing
worldwide as a consequence mainly of either ischemic
or hypertensive heart disease, and also because of spe-
cific myocardial diseases such as dilated cardiomyopathy
(DCM). Hypertrophic growth accompanies many forms
of heart failure, and, in fact, left ventricular hypertrophy
is a major predictor of systolic heart failure [6]. Although
many mechanisms have been shown to be involved in
cardiac dysfunction, little is known about the molecular
pathways underlying heart disease.
The understanding that one gene can encode more than
a single protein product as a result of transcriptional and
translational processes has led to the concept that the
functional complexity of an organism far exceeds that
indicated by its genome sequence alone. Furthermore,
protein maturation, degradation, and post-translational
modifications are dynamic processes that can control the
amount of functionally active protein within a cell. It is
estimated that in humans there are approximately 6 to 7
times more proteins than genes. Proteins also show com-
plexity because of their primary, secondary, tertiary, and
quaternary structural elements [7].
In this sense, proteomic analysis has been shown to
provide novel information about protein expression in
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different settings, usually by combining bi-dimensional
separation of proteins (2-DE) and mass spectrometry
(MS) [8]. The application of proteomics provides major
opportunities for a more comprehensive understanding
of cell and organ function and dysfunction, providing new
avenues to elucidate disease mechanisms and to identify
new diagnostic biomarkers and therapeutics targets.
KNOWN MARKERS AND RISK FACTORS
OF CVD
The outstanding progress in cardiovascular medicine
allows for a very high level of success in managing patients
with CVD. With the advent of new effective treatments
for hypertension and more efficient management of acute
myocardial infarction, deaths resulting from stroke and
acute coronary syndromes have steadily decreased [9].
However, CVD is still associated with high morbidity and
mortality rates [10, 11].
Both atherosclerotic vascular disease and heart failure
are characterized by a period of silent disease, with no
overt clinical manifestations. It is important to consider
that nowadays there are many effective treatments to
slow the progress and even stabilize both processes, with
demonstrated survival benefits. The potential to know the
presence of any of these diseases in previously asymp-
tomatic individuals may permit the use of specific ther-
apeutic approaches and lifestyle modification plans that
may alter the natural history of such important diseases in
the initial phase. Recent clinical trials on primary and sec-
ondary prevention of adverse cardiovascular events have
shown this potential, although patient selection in these
trials has been limited by the knowledge of the increased
risk of adverse events based only on clinical data. The po-
tential for prevention in a more stable population is one
of the major challenges in cardiovascular medicine. Al-
though it is well known that classical risk factors are asso-
ciated with the presence of cardiovascular events, we still
need additive prognostic markers to predict this risk more
accurately. Although noninvasive imaging techniques are
being investigated in this setting, these techniques cannot
be applied to a wide population range to the same extent
as can the new potential prognostic biomarkers.
The most extensively studied potential biomarker
for atherosclerosis to date has been C-reactive protein
(CRP). Prospective studies have demonstrated that high
CRP levels are associated with an increase of cardiovas-
cular risk in apparently healthy men [12]. In this regard,
it is actually accepted that patients with CRP levels lower
than 1 mg/L, between 1 and 3 mg/L, or higher than 3 mg/L
show low, medium, or high risk, respectively, of devel-
oping cardiovascular disease. Although CRP could be
used to stratify risk situations, it appears to have mod-
erate predictive value [13], and it has not gained wide
acceptance in clinical practice. In addition to CRP, many
markers of systemic inflammation have been studied in
recent years as potential candidates for risk prediction
[14]. In this sense, it has been observed that increased
plasma CD40L levels predict a higher risk of cardiovas-
cular events in healthy women [15]. Other markers of
CVD are monocyte chemo-attractant protein-1, adhesion
molecules, myeloperoxidase, and several interleukins.
Nevertheless, none have been consistently demonstrated
to add predictive value to the clinical variables used in
clinical practice, and, in most cases, there are no com-
mercially available standardized assays [14]. Despite the
available biomarkers of cardiac necrosis and ventricu-
lar failure, like B-type natriuretic peptides, new specific
biomarkers for different stages of the disease or the in-
farct size are necessary to better predict prognosis in these
patients.
PROTEOMICS STUDY OF CVD
Today, it is possible to perform a differential proteomic
analysis on a variety of biologic samples, including cells,
tissues, or biologic fluids. Atherosclerosis is characterized
by focal plaques from which proteins can diffuse in low
amounts and be retrieved from plasma. In the context
of biomarker discovery, biologic fluids such as plasma
or urine seem to be the most logical samples for inves-
tigation. Plasma proteomic studies still show important
difficulties because of the presence of large amounts of
albumin that may mask key potential protein biomark-
ers. However, recent technologic improvements permit
depletion of such abundant plasma proteins and increase
the potential of plasma-proteomic analysis to find rele-
vant biomarkers. Another approach consists of the anal-
ysis of either vascular cells under pathologic conditions,
atherosclerotic plaques, or cardiac tissue, by comparison
with healthy cells or tissues.
Proteomic analysis of atherosclerotic plaques
A particular issue in proteomic analysis of vascular
pathology is the heterogeneous cellular composition of
the vascular wall (endothelial cells, smooth muscle cells,
leukocytes, and so forth). The first published proteomic
study of human atherosclerosis was performed on tis-
sue extracts, and the only detected changes corresponded
to plasma proteins (albumin, immunoglobulin G, Apo-I,
and so forth) [16]. Years later, You et al showed an
increase in ferritin light chain expression in coronary
arteries from 10 patients with coronary artery disease
compared with seven healthy controls [17]. However, the
proteomic analysis of a tissue probably identifies mainly
constitutive proteins and may under-represent potential
biomarkers. A different approach was carried out by
Martinet et al [18] with Western array technology to iden-
tify differentially expressed proteins of potential patho-
biological relevance in human atherosclerotic plaques.
Tissue lysates from human carotid endarterectomy spec-
imens and non-atherosclerotic mammary arteries were
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screened with 823 monoclonal antibodies. They identi-
fied seven proteins with a >5-fold relative expression.
One of the most interesting downregulated proteins in
atherosclerotic plaques was apoptosis-linked gene 2, a re-
cently discovered pro-apoptotic protein that belongs to
a Ca2+-binding protein family with EF-hand motifs [19].
Apoptosis has been identified as a prominent feature of
advanced human atherosclerotic plaques [20], so these
findings may shed light on how macrophage-derived foam
cells survive pro-apoptotic signaling in human plaques.
Proteomic analysis of the tissue secretome
An alternative approach for the study of atheroscle-
rotic plaque proteins released by normal and pathologic
arterial walls has recently been used by the authors and
others [21]. This consists of the analysis of proteins se-
creted to the media by normal and pathologic explanted
arteries. In addition, the incubation of complicated and
noncomplicated endarterectomy samples in a protein-
free culture medium allowed us to harvest separately the
proteins released from these vessels. Two-dimensional
electrophoresis of this “secretome” showed that normal
artery segments secreted at least 40 different proteins,
compared with atherosclerotic vessels that were shown
to secrete almost 80 proteins. The protein spots were also
higher in the 2-DE gels of artery segments with a ruptured
plaque and thrombus [21]. Interestingly, our preliminary
data show an increased secretion of protein disulfide iso-
merase by atherosclerotic plaques, a protein recently con-
sidered a major proinflammatory mediator involved in
atherosclerosis [22, 23].
Among the differentially secreted proteins, decreased
heat shock protein-27 (Hsp27) was identified as a poten-
tial marker of atherosclerosis [24]. In this study, when
compared with control mammary arteries, Hsp27 release
was drastically decreased in atherosclerotic plaques and
barely detectable in complicated plaque supernatants. In
addition, Hsp27 production by arterial wall correlates
negatively with atherosclerotic plaque complexity. Fur-
thermore, we have measured circulating plasma levels of
Hsp27 in patients with carotid atherosclerosis (stenosis
>70%) and in healthy patients. Circulating Hsp27 levels
were decreased 20 fold in patients with carotid atheroscle-
rosis relative to healthy patients [24], indicating that
plasma protein content can reflect arterial wall secre-
tion of this protein. These data suggest that low levels of
plasma Hsp27 could be a potential marker of atheroscle-
rosis, although the pathologic meaning of this diminution
of plasma Hsp27 requires further investigation.
In the same study, two Hsp27 isoforms were iden-
tified by matrix-assisted laser desorption/ionization
mass spectrometry peptide mapping, corresponding to
the nonphosphorylated (isoform 2) and the mono-
phosphorylated state of Hsp27, with Ser82 as the modi-
fied residue (isoform 1). Although the exact role of Hsp27
in atherosclerosis is unknown, previous data suggest that
Hsp27 could play a protective role. This protein is ex-
pressed in endothelial and vascular smooth muscle and
is able to bind and stabilize actin microfilaments, favor-
ing the formation of actin stress fibers. Hsp27 has also
been implicated in the apoptosis process by downreg-
ulating key apoptotic signaling pathways [25]. Finally,
Hsp27 could also interfere with the inflammatory re-
sponse present in atherosclerotic lesions by inhibiting nu-
clear factor kappa B activation [26]. These examples show
how proteomics can be a useful technique to identify not
only new proteins involved in the pathogenesis of CVD,
but also the specific post-translational modifications as-
sociated with the disease process.
Further studies are in progress to fully identify and
define the role of these proteins in atherogenesis and their
potential role to be novel markers/therapeutic targets of
cardiovascular risk.
Proteomic analysis of cardiac diseases
As mentioned above, a particular problem in pro-
teomic analysis of the heart is the diversity of cell types
present in the vascular wall. Protein expression patterns
of total myocardial lysates are predominately due to the
cardiac myocyte proteins, but these samples will also con-
tain lower amounts of proteins derived from other cell
types such as fibroblasts and smooth muscle and endothe-
lial cells [27]. Recently, proteomic techniques have been
coupled with other research fields, with laser capture mi-
crodissection [28]. This powerful combination allows the
isolation of specific cell types from tissue sections, which
overcomes the problem of tissue heterogeneity [29]. This
combination is beginning to be used in the cardiovascular
field. However, the difficulties and ethical problems in ob-
taining human heart samples make it necessary to study
heart disease through indirect approaches. The study of
heart diseases in established animal models, such as dogs
for the DCM or spontaneously hypertensive rats for heart
failure or hypertrophied heart, make it possible to iden-
tify altered proteins specific to the disease, which will be
a potential specific biomarker or new therapeutic tar-
get. Using a bovine model of hereditary DCM, it has
been found that from more than 1000 resolved proteins,
24 proteins were decreased and 11 were increased in
pathologic versus control tissue [30]. The identification
by MS of some of the altered proteins allows us to con-
clude that inappropriate protein ubiquitination plays a
major role in DCM [30]. Other authors, using a model
of pacing-induced heart failure, showed that heart fail-
ure is associated with changes in the protein expression
involving mitochondrial energy production, cytoskeletal
architecture, and calcium-regulated processes [31, 32].
Particularly, diminished expression of mitochondrial
hydroxylmethyl glutaryl coenzyme A synthase was
observed, consistent with the hypothesis of reduced
mitochondrial energy supply during DCM. They also











Fig. 1. (A) Representative image of 2-DE gel from left ventricular samples, showing 15 altered protein spots (squares) compared with normal
heart. As an example, we show the identification of one of these altered proteins (arrow). (B) Peptide mass fingerprint spectrum was obtained on a
Bruker Ultraflex TOF/TOF MALDI mass spectrometer (Bruker-Daltonics GmbH, Bremen, Germany). (C) The measured tryptic peptide masses
were transferred through the MS BioTools program (Bruker-Daltonics) as inputs to search the MSBD database using Mascot software (Matrix
Science, London, UK). This spot protein was positively identified as mitochondrial adenosine triphosphate synthase D chain.
noted an increased level of several glycolytic enzymes,
which is probably a compensatory mechanism to counter-
act insufficient mitochondrial energy production [31, 32].
The process of myocardial necrosis leads to the release
of proteins from dead myocytes into the circulation and
hence provides relatively accessible targets to identify
biomarkers. The original biomarkers used in myocardial
necrosis diagnostics included serum glutamate oxaloac-
etate transferase, lactate dehydrogenase, and creatine ki-
nase, specifically the MB isoform. Recently, the use of
troponin-I and troponin-C increased the sensibility of
myocardial necrosis. The clinical utility of these mark-
ers has been extensively demonstrated, but there may
still be room for improvement. Several animal studies
have investigated changes in the protein profile in the
myocardium after ischemia-reperfusion injury. Sakai et
al identified rat myocardial proteins altered on ischemia
by using fluorescence-based two-dimensional polyacry-
lamide gel electrophoresis (2D-PAGE) [33]. Likewise,
Schwertz et al have found marked differences in pro-
tein expression in a rabbit model of myocardial ischemia-
reperfusion [34].
Proteomic analysis of the diseased heart may allow
for the identification of markers specific for heart dis-
eases (valvular, congenital, and so forth) of potential
clinical interest. In addition, proteomic studies of the
heart under different pathologic states will give impor-
tant information regarding cardiac physiology that may
be useful in finding specific therapeutic targets to im-
prove the prognosis of these patients. Of special inter-
est is hypertension-induced left ventricular hypertrophy,
in which the diagnosis still relies basically on echocar-
diographic data. The increasing hypertensive popula-
tion and the lack of tight blood pressure control in this
group of patients make it a condition of special inter-
est for research into a specific marker. This will allow
us to closely monitor hypertensive patients and may
help to prevent this condition, which, if unrecognized,
would progress to overt heart failure. We are studying
the proteome of hypertension-induced early left ven-
tricle hypertrophy in a spontaneously hypertensive rat
model. Through a proteomic approach from 464 ana-
lyzed protein spots, we have found significant differences
in 15 cardiac protein spots in a rat model of early left
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ventricular hypertrophy. Some of these altered spots have
been identified by MS, which belong to contractile pro-
teins (tropomyosin alpha-chain) and oxidative phospho-
rylation complex (adenosine triphosphate synthase D
chain, mitochondrial) (Fig. 1). These findings suggest an
inadequate aerobic metabolism in the early-hypertrophy
cardiomyocytes.
Although a great deal of research effort is currently
underway to find new biologic markers of CVD, it is clear
that proteomic analysis is one of the most powerful tools
available for this purpose.
CONCLUSION
The use of new techniques, such as proteomic analysis,
will permit the analysis of multiple proteins in blood. This
approximation will give us the opportunity to explore a
lot of possible risk markers and evaluate which are the
most appropriate for clinical use. On the other hand, use
of new markers probably will serve us to analyze the effect
of diverse treatments in different patients and adequate
them to the characteristics of each patient. Furthermore,
a set of markers (multipanel) could potentially give more
information about different levels of the disease and will
be of more clinical benefit for us from a prognostic point
of view.
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